Vivienne Milch
Professorial Fellow
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (21)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Background and Objective Genomic medicine offers an unprecedented opportunity to improve cancer outcomes through prevention, early detection and precision therapy. Health policy makers worldwide are developing strategies to embed genomic medicine in routine cancer care. Successful translation of genomic medicine, however, remains slow. This systematic review aims to identify and synthesise published evidence on the cost effectiveness of genomic medicine in cancer control. The insights could support efforts to accelerate access to cost-effective applications of human genomics. Methods The study protocol was registered with PROSPERO (CRD42024480842), and the review was conducted in line with Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) Guidelines. The search was run in four databases: MEDLINE, Embase, CINAHL and EconLit. Full economic evaluations of genomic technologies at any stage of cancer care, and published after 2018 and in English, were included for data extraction. Results The review identified 137 articles that met the inclusion criteria. Most economic evaluations focused on the prevention and early detection stage ( n = 44; 32%), the treatment stage ( n = 36; 26%), and managing relapsed, refractory or progressive disease ( n = 51, 37%). Convergent cost-effectiveness evidence was identified for the prevention and early detection of breast and ovarian cancer, and for colorectal and endometrial cancers. For cancer treatment, the use of genomic testing for guiding therapy was highly likely to be cost effective for breast and blood cancers. Studies reported that genomic medicine was cost effective for advanced and metastatic non-small cell lung cancer. There was insufficient or mixed evidence regarding the cost effectiveness of genomic medicine in the management of other cancers. Conclusions This review mapped out the cost-effectiveness evidence of genomic medicine across the cancer care continuum. Gaps in the literature mean that potentially cost-effective uses of genomic medicine in cancer control, for example rare cancers or cancers of unknown primary, may be being overlooked. Evidence on the value of information and budget impact are critical, and advancements in methods to include distributional effects, system capacity and consumer preferences will be valuable. Expanding the current cost-effectiveness evidence base is essential to enable the sustainable and equitable translation of genomic medicine.
Year:
2025
Background and Aim Historical genetic sequencing of specific cancer variants has been superseded by comprehensive genomic profiling (CGP). This narrative review aimed to capture current international evidence on the clinical utility of CGP for cancer prevention, detection and treatment. Materials and Methods A literature search of three databases was performed to identify key studies on the frequency of germline and somatic variants in adult cancers and the extent to which they inform diagnosis, management and outcome. Findings were inductively mapped and narratively synthesised. Results Consolidated results from 95 original research papers showed that pathogenic germline (familial) variants are found in ~10% of adults with cancer, of whom 53%–61% are offered germline genotype‐directed treatment. Importantly, 50% of germline carriers would not have satisfied the eligibility criteria for genetic testing and/or reported a negative family history. Actionable somatic variants occur in 27%–88% of cases, which markedly impact the diagnosis for cancers of unknown primary. Matched treatments were identified for 31%–48% of cancer patients, of whom 33%–45% received it. Response and survival rates were better in individuals receiving matched therapies compared to those receiving standard of care or unmatched therapies. Trials show that circulating tumour DNA (ctDNA) assays are feasible and sensitive. The relatively non‐invasive ctDNA sample collection is appealing for cancers with inaccessible or unknown primary sites, and serial monitoring of residual disease and/or treatment response. Conclusions As matched therapies are underutilised due to declining patient condition and fewer prior therapies predicting better response rates, research is needed on the suitability of cancer genomic profiling as a frontline test.
Year:
2025
Year:
2025
Year:
2025
BACKGROUND Young people undergoing cancer treatment are at increased risk of severe COVID-19 outcomes. Vaccination is recommended; however, data regarding vaccine response are limited. METHODS A prospective cohort study was conducted of children and adolescents (aged 5–19 years) with current solid or hematological cancer and life expectancy of at least 1 year, eligible for COVID-19 vaccination. Participants received 2 or 3 doses of BNT162b2. Blood was taken at baseline, after dose 1, and then 1 and 3 months after subsequent doses. Safety outcomes and patient-reported adverse events were collected. The proportion with neutralizing antibody (NAb) response after 2 vaccine doses was the primary outcome. Vaccine response was measured by NAb titer (positive ≥1:20), T-cell response (interferon-γ, positive ≥10 pg/mL), and binding antibody titer. RESULTS Of 113 patients enrolled, 108 (96%) currently or previously received cytotoxic chemotherapy, and most were on current or recent therapy, with 18 (16%) having completed treatment more than 6 months prior to vaccination. Positive NAb response occurred in 52/79 (66%) with samples available after 2 doses and 33/41 (80%) after 3 doses. Interferon-γ response occurred in 44/64 (59%) after 2 doses and 25/34 (74%) after 3 doses. Adverse events were generally mild to moderate, were transient if serious (fever, mucositis, headache), and did not delay cancer treatment. Fever was reported by 12% after doses 1 and 2 and 15% after dose 3. CONCLUSIONS Most children with cancer respond to BNT162b2 COVID-19 vaccination despite anticancer treatment. Vaccination should not be deferred until treatment completion. These data may have implications for other childhood vaccinations during cancer treatment.
Year:
2025
Finite clinical genetics services combined with expanding genomic testing have driven development of mainstreaming models‐of‐care for genomic testing: specifically genetic counselor embedded (GEM) and upskilled‐clinician (UPC) models. To determine feasibility, acceptability, and health economic impact in cancer mainstreaming settings we conducted a scoping review of the literature. A comprehensive PubMed search identified relevant manuscripts, published in English between 2013 and 2023. Of 156 identified articles, 37 proceeded to full review, encompassing five cancer types. In both models‐of‐care, testing uptake was > 90% and referral/testing rates increased 1.2–6.7‐fold. Time from diagnosis to result disclosure decreased 1.5–6‐fold and pathogenic variant detection rates were ≥ 10%. GEM model studies evaluated neither cost‐effectiveness nor physician/patient outcomes. UPC models were economically viable, primarily through reducing genetics‐related appointments. Physicians found the UPC model workload acceptable and reported improvements in knowledge and confidence. Patient distress in the UPC model was low overall and comparable to standard‐of‐care. Patients' acceptance and satisfaction/decisional satisfaction were high, and continuity‐of‐care was appreciated. Mainstreaming cancer genomic testing is feasible and beneficial to patients, physicians, and healthcare systems. More studies are needed to capture GEM model impacts and to compare GEM with UPC models. Further detail of allied health and nursing support for the UPC model is also required.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Collaborators (30)
Jolyn Johal
Flinders University
Fiona Crawford-Williams
Flinders University
Jacqueline Roseleur
Flinders University
Jon Emery
Professor of Family Medicine. Director of Research Institute for Cancer Prevention, Screening and Early Detection (RISE)
Nanyang Technological University (NTU)
Li Huang
Senior Research Fellow
University of Melbourne
Eva Segelov
MONASH UNIVERSITY
Lisa Whop
Associate Professor, National Centre for Aboriginal and Torres Strait Islander Wellbeing Research
Australian National University
Ainsley Newson
Professor of Bioethics
University of Sydney
Raglan Maddox
Australian National University
Oluwaseyifunmi Agbejule
Flinders University
Stephen Opat
Monash Health
Raymond Chan
Flinders University
Phil Crosbie
Manchester University NHS Foundation Trust
Rebekah McWhirter
Australian National University
chad Yixian Han
Flinders University
Imogen Ramsey
Flinders University
Abbey Diaz
Senior Research Fellow
Australian National University
Kylee Bellingham
University of Melbourne
Aideen McInerney‐Leo
Research Leader
University of Queensland
Peter Downie
Head of Unit
Monash Health
Fanny Franchini
Senior Research Fellow
University of Melbourne
Alex Brown
Professor
Telethon Kids Institute
Reegan Knowles
Flinders University
Susan J. Jordan
Associate Profesor
University of Queensland
Ria Joseph
Flinders University
Nicolas Hart
Associate Professor, Program Director, NHMRC Fellow
Queensland University of Technology
Matthew Wallen
Flinders University
Matthew Tieu
Flinders University
Jean-Luc Bulliard
Head of sector Epidemiology and Data Science & Scientific Director of Neuchâtel-Jura Cancer Registry
Centre for Primary Care and Public Health (Unisanté), University of Lausanne
Julie Ratcliffe
Flinders University
Make your next move.
Prepare your application
Review drafts before you send them.